President Donald Trump has locked in a sweeping set of pricing agreements with nine of the world's biggest drugmakers, ...

In his latest effort to lower drug costs, President Donald Trump unveiled Friday “Most Favored Nation” pricing deals with nine more pharmaceutical companies.

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug pricing deals.

Large pharmaceutical companies are entering a period of renewed relevance as therapeutic innovation accelerates, particularly ...

President Donald Trump announced he would be placing new tariffs on pharma products on October 1st, in the latest development of the administration’s ongoing trade war. In a Truth Social post, Trump ...

Pharma marketers enter 2026 asking where DTC fits in the DTP era.  | Pharma marketers enter 2026 asking where DTC fits in the ...

The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S.

Big Pharma sees Chinese pharma and biotech companies as increasingly attractive to do deals with as the quality of work coming from those companies has been steadily increasing, according to two U.S.

President Donald Trump signed a memo on Sept. 9 to increase enforcement actions against companies that use direct-to-consumer pharmaceutical advertisements and do not adequately disclose side effects ...

The market for weight-loss drug is expected to expand to more than $150 billion in revenue by the early 2030s, thanks to the ...

President Donald Trump's clamp-down on federal science funding has handed Big Pharma an existential headache: the National Institutes of Health (NIH) has terminated more than 2,100 research grants and ...

Low compliance by the country’s 8,500 small and medium enterprises (MSMEs) manufacturing pharmaceuticals would raise the risk ...